Baker McKenzie and Vischer on SHS’s investment in Simulands
The German life science and medtech private equity firm SHS Capital has made a EUR 10 million investment in Simulands, a Swiss manufacturer of simulation devices for medical training of cardiovascular interventions.
The investment aims to accelerate the commercialization of this early-stage company and to help it revolutionize cardiovascular education and training. Simulands plans to accelerate its commercialization strategy for its cardiac intervention training equipment.
Founded in Zurich in 2019, Simulands has been growing rapidly, already establishing a strong reputation for its medical simulation training tools. The company creates tools that enable cardiologists to train in the safe performance of complex cardiovascular interventions.
Baker McKenzie Switzerland has advised Simulands on all legal aspects of the deal. The team was led by m&a partner Manuel Meyer (pictured left) and included m&a associates Christian Rioult and Hesam Mirzai.
VISCHER has advised SHS on all legal aspects of this transaction. The team was led by Christian Gutzwiller (senior associate, corporate/m&a, pictured right) and Jürg Luginbühl (partner, corporate/m&a) and included Stefan Kohler (partner, IP/regulatory), Elias Mühlemann (managing associate, IP/Data & Privacy), Dan Pruschy (associate, IP/regulatory) and Gordana Nisevic (corporate/m&a).
